Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population

被引:300
作者
Savès, M
Chêne, G
Ducimetière, P
Leport, C
Le Moal, G
Amouyel, P
Arveiler, D
Ruidavets, JB
Reynes, J
Bingham, A
Raffi, F
机构
[1] Univ Bordeaux 2, INSERM, U593, U330, F-33076 Bordeaux, France
[2] INSERM, U258, Villejuif, France
[3] Fac Xavier Bichat, Lab Rech Pathol Infect, Paris, France
[4] CHU Jean Bernard La Miletrie, Poitiers, France
[5] Inst Pasteur, INSERM, U508, F-59019 Lille, France
[6] Fac Med, Lab Epidemiol & Sante Publ, Strasbourg, France
[7] Univ Toulouse 3, INSERM, U558, Dept Epidemiol, F-31062 Toulouse, France
[8] Hop Gui de Chauliac, Serv Malad Infect, Montpellier, France
[9] Hop Hotel Dieu, Serv Malad Infect, Nantes, France
关键词
D O I
10.1086/375844
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The distribution of risk factors for cardiovascular disease in patients aged 35-44 years who were treated for human immunodeficiency virus type 1 (HIV-1) infection was compared with that for a population-based cohort. HIV-1-infected men treated with a protease inhibitor-containing regimen (n=223), compared with HIV-1-uninfected men (n=527), were characterized by a lower prevalence of hypertension, a lower mean high-density lipoprotein cholesterol level, a higher prevalence of smoking, a higher mean waist-to-hip ratio, and a higher mean triglyceride level. No difference was found for total plasma or low-density cholesterol levels, nor for the prevalence of diabetes. Similar trends were observed among female subjects. The predicted risk of coronary heart disease was greater among HIV-1-infected men (relative risk [RR], 1.20) and women (RR, 1.59; P<10(-6) for both), compared with the HIV-1-uninfected cohort. The estimated attributable risks due to smoking were 65% and 29% for HIV-1-infected men and women, respectively. Because most HIV-1-infected people will ultimately need antiretroviral therapy, risk factors for cardiovascular disease should be determined at the initiation of treatment, and interventions should be considered for all patients who have them.
引用
收藏
页码:292 / 298
页数:7
相关论文
共 23 条
[1]   CARDIOVASCULAR-DISEASE RISK PROFILES [J].
ANDERSON, KM ;
ODELL, PM ;
WILSON, PWF ;
KANNEL, WB .
AMERICAN HEART JOURNAL, 1991, 121 (01) :293-298
[2]  
Behrens G, 1998, LANCET, V351, P1958, DOI 10.1016/S0140-6736(98)26026-0
[3]   Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens [J].
Bonnet, F ;
Savès, M ;
Droz, C ;
Peuchant, E ;
Chêne, G ;
Beylot, J ;
Morlat, P .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 25 (02) :199-200
[4]   Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection [J].
Bozzette, SA ;
Ake, CF ;
Tam, HK ;
Chang, SW ;
Louis, TA .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (08) :702-710
[5]   Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study [J].
Carr, A ;
Samaras, K ;
Thorisdottir, A ;
Kaufmann, GR ;
Chisholm, DJ ;
Cooper, DA .
LANCET, 1999, 353 (9170) :2093-2099
[6]   A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors [J].
Carr, A ;
Samaras, K ;
Burton, S ;
Law, M ;
Freund, J ;
Chisholm, DJ ;
Cooper, DA .
AIDS, 1998, 12 (07) :F51-F58
[7]   Cardiovascular risk associated with HIV therapy [J].
Currier, JS .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 :S16-S23
[8]   Premature atherosclerosis in HIV-infected individuals - focus on protease inhibitor therapy [J].
Depairon, M ;
Chessex, S ;
Sudre, P ;
Rodondi, N ;
Doser, N ;
Chave, JP ;
Riesen, W ;
Nicod, P ;
Darioli, R ;
Telenti, A ;
Mooser, V .
AIDS, 2001, 15 (03) :329-334
[9]   Five-year incidence of angina pectoris and other forms of coronary heart disease in healthy men aged 50-59 in France and Northern Ireland:: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study [J].
Ducimetière, P ;
Ruidavets, JB ;
Montaye, M ;
Haas, B ;
Varnell, J .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2001, 30 (05) :1057-1062
[10]   Highly active antiretroviral therapy and coronary heart disease: the need for perspective [J].
Egger, M ;
Junghans, C ;
Friis-Moller, N ;
Lundgren, JD .
AIDS, 2001, 15 :S193-S201